FINE-ONE
Summary
In this study, participants with type 1 diabetes will take a new medication that has been shown to reduce kidney disease in people living with type 2 diabetes. This medication is called finerenone. No other medication on the market has been shown to reduce kidney disease. Participants will visit with a study nurse about 6 times over 7 months to get study medication and complete blood work.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 100
Inclusion criteria:
1. Over 18 years of age
2. Living with Type 1 Diabetes
3. Have been diagnosed with chronic kidney disease (CKD)
Exclusion criteria:
1. People with Type 2 Diabetes
Participate
Additional information
Contact information
Amy Dunlop
Principal investigator:
Ronald Sigal
Clinical trial:
Yes
REB-ID:
REB23-0867